Alterity Therapeutics (ATHE) Institutional Ownership $4.08 -0.11 (-2.63%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.00 -0.08 (-1.96%) As of 02/21/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Alterity Therapeutics (NASDAQ:ATHE)CurrentInstitutional OwnershipPercentage2.14%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$163.90KNumber ofInstitutional Sellers(last 12 months)0 Get ATHE Insider Trade Alerts Want to know when executives and insiders are buying or selling Alterity Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ATHE Institutional Buying and Selling by Quarter Alterity Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025 Point72 Asset Management L.P.32,627$108K0.0%N/A0.373% 2/17/2025 BNP Paribas Financial Markets8,790$29K0.0%N/A0.101% 1/15/2025 HB Wealth Management LLC31,883$110K0.0%+34.1%0.436% 2/4/2022 Envestnet Asset Management Inc.82,386$59K0.0%N/A0.364% 8/13/2021 Renaissance Technologies LLC237,903$309K0.0%+5.9%1.052% 5/21/2021 Citadel Advisors LLC65,011$94K0.0%N/A0.288% 5/19/2021 Virtu Financial LLC69,905$101K0.0%N/A0.309% 5/18/2021 Morgan Stanley627,907$904K0.0%+7.9%2.778% 5/18/2021 Citadel Advisors LLC65,011$94K0.0%N/A0.288% 5/13/2021 Renaissance Technologies LLC224,690$324K0.0%-30.1%0.994% 2/10/2021 Renaissance Technologies LLC321,500$431K0.0%+98.2%1.422% (Data available from 1/1/2016 forward) ATHE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ATHE shares? During the previous two years, the following institutional investors and hedge funds held shares of Alterity Therapeutics shares: HB Wealth Management LLC ($110K), and Point72 Asset Management L.P. ($108K), BNP Paribas Financial Markets ($29K).Learn more on ATHE's institutional investors. What percentage of Alterity Therapeutics stock is owned by institutional investors? 2.14% of Alterity Therapeutics stock is owned by institutional investors. Learn more on ATHE's institutional investor holdings. Which institutional investors have been buying Alterity Therapeutics stock? The following institutional investors have purchased Alterity Therapeutics stock in the last 24 months: Point72 Asset Management L.P. ($32.63K), BNP Paribas Financial Markets ($8.79K), and HB Wealth Management LLC ($8.10K). How much institutional buying is happening at Alterity Therapeutics? Institutional investors have bought a total of 49,517 shares in the last 24 months. This purchase volume represents approximately $163.90K in transactions. Related Companies ENTA Institutional Ownership ACTU Institutional Ownership NVCT Institutional Ownership TIL Institutional Ownership LXEO Institutional Ownership ADAP Institutional Ownership STRO Institutional Ownership SLN Institutional Ownership MCRB Institutional Ownership PBYI Institutional Ownership This page (NASDAQ:ATHE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
